Cite
MLA Citation
Evan Yu et al.. “345 Phase 3 study of combination pembrolizumab + olaparib therapy versus enzalutamide/abiraterone in metastatic castration-resistant prostate cancer (mCRPC) after progression on chemotherapy (KEYLYNK-010).” Journal for immunotherapy of cancer, vol. 8, n.d., p. A370. http://access.bl.uk/ark:/81055/vdc_100144719126.0x000004